Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Controlled Clinical Trial
. 2017 Nov;60(11):2192-2199.
doi: 10.1007/s00125-017-4299-y. Epub 2017 Aug 23.

Effect of screening for type 2 diabetes on risk of cardiovascular disease and mortality: a controlled trial among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009

Rebecca K Simmons  1   2   3   4 , Simon J Griffin  5   6   7 , Torsten Lauritzen  5 , Annelli Sandbæk  5
Affiliations
Controlled Clinical Trial

Effect of screening for type 2 diabetes on risk of cardiovascular disease and mortality: a controlled trial among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009

Rebecca K Simmons et al. Diabetologia. 2017 Nov.

Abstract

Aims/hypothesis: There is continuing debate about the net benefits of population screening for type 2 diabetes. We compared the risk of cardiovascular disease (CVD) and mortality among incident cases of type 2 diabetes in a screened group with those in an unscreened group.

Methods: In this register-based non-randomised controlled trial, eligible individuals were all men and women aged 40-69 years without known diabetes, registered with a general practice in Denmark (n = 1,912,392). Between 2001 and 2006, 153,107 individuals registered with 181 practices participating in the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION)-Denmark study were sent a diabetes-risk-score questionnaire. Individuals at moderate-to-high risk were invited to visit their family doctor for assessment of diabetes status and cardiovascular risk (screening group). The 1,759,285 individuals registered with all other practices in Denmark constituted the retrospectively constructed no-screening (control) group. In this post hoc analysis, we identified individuals from the screening and no-screening groups who were diagnosed with diabetes between 2001 and 2009 (n = 139,075), and compared risk of CVD and mortality in these groups between 2001 and 2012.

Results: In the screening group, 27,177/153,107 (18%) individuals attended for screening, of whom 1533 were diagnosed with diabetes. Between 2001 and 2009, 13,992 people were newly diagnosed with diabetes in the screening group (including those diagnosed by screening) and 125,083 in the no-screening group. Between 2001 and 2012, the risks of CVD and mortality were lower among individuals with diabetes in the screening group compared with individuals with diabetes in the no-screening (control) group (CVD HR 0.84, 95% CI 0.80, 0.89; mortality HR 0.79, 95% CI 0.74, 0.84).

Conclusions/interpretation: A single round of diabetes screening and cardiovascular risk assessment in middle-aged Danish adults in general practice was associated with a significant reduction in risk of all-cause mortality and CVD events in those diagnosed with diabetes.

Keywords: Cardiovascular disease; General practice; Mortality; Population; Screening; Trial; Type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

Data availability

The data used in this paper are a combination of data obtained from the ADDITION study and data from the national Danish Registers at Statistics Denmark (DST). The ADDITION study data were obtained after a written application to the data owner, A. Sandbæk (Institute of Public Health, Aarhus University, Aarhus, Denmark; annelli.sandbaek@ph.au.dk). Data from DST were made available following an application to DST (www.dst.dk/en/TilSalg/Forskningsservice). Data from ADDITION and DST were merged by DST and analyses were performed via a secure virtual private network (VPN) connection. In accordance with the Danish Act on Processing of Personal Data, future interested researchers must perform the steps mentioned above to obtain access to the data.

Duality of interest

RKS is supported by the Danish Diabetes Academy under a Visiting Professorship. The Danish Diabetes Academy is funded by the Novo Nordisk Foundation. RKS is further supported by the Aarhus Institute of Advanced Studies. SJG’s research programme is supported by MRC Epidemiology Unit core funding (MC_UU_12015/4). SJG is an NIHR Senior Investigator and a member of the NIHR School for Primary Care Research. SJG receives an honorarium and reimbursement of travel expenses from Eli Lilly associated with membership of an independent data monitoring committee for a randomised trial of a medication to lower glucose. SJG received an honorarium from Janssen for speaking at an educational meeting in 2015. TL holds shares in Novo Nordisk A/S. TL reports receiving a fee for attending an international board meeting for Astra Zeneca on early detection and treatment of diabetes in 2015. AS reports receiving lecture fees for providing continuing medical education to general practitioners.

Contribution statement

RKS and AS had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. RKS conducted and is responsible for the data analysis.

RKS and AS act as guarantors for this paper. AS and TL designed the ADDITION-Denmark study, and are principal investigators for the trial. SJG conceived the study question for this paper. SJG, TL, AS and RKS developed the study proposal. AS and RKS participated in the acquisition of the data from Statistics Denmark. RKS analysed the data and drafted the report. RKS, SJG, TL and AS participated in the interpretation of the data, the critical revision of the report for important intellectual content and gave final approval for this version to be published. RKS, TL and AS provided administrative, technical and material support for the study.

Figures

Fig. 1
Fig. 1
Visual representation of sampling frame. The ‘S’ in a blue circle denotes individuals detected by the ADDITION stepwise screening programme. The ‘C’ in a red circle denotes individuals with clinically diagnosed diabetes
Fig. 2
Fig. 2
Cumulative incidence of all-cause mortality in individuals with diabetes in the screening and no-screening groups (2001 to 2012). The model is unadjusted. Solid line, no-screening (control) group; dashed line, screening group
Fig. 3
Fig. 3
Cumulative incidence of a composite CVD event among individuals with diabetes in the screening and no-screening groups (2001 to 2012). The model is unadjusted. Solid line, no-screening (control) group; dashed line, screening group
See this image and copyright information in PMC

Comment in

References

    1. Kuo HS, Chang HJ, Chou P, Teng L, Chen TH. A Markov chain model to assess the efficacy of screening for non-insulin dependent diabetes mellitus (NIDDM) Int J Epidemiol. 1999;28:233–240. doi: 10.1093/ije/28.2.233. - DOI - PubMed
    1. Chang HJ, Kuo HS, Tung TH, Chou P, Chen TH. Evaluation of a population-based screening for type 2 diabetes: a community-based screening project in Puli, Taiwan. Prev Med. 2000;31:396–402. doi: 10.1006/pmed.2000.0728. - DOI - PubMed
    1. Kahn R, Alperin P, Eddy D, et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet. 2010;375:1365–1374. doi: 10.1016/S0140-6736(09)62162-0. - DOI - PubMed
    1. Schuetz CA, Alperin P, Guda S, et al. A standardized vascular disease health check in europe: a cost-effectiveness analysis. PLoS One. 2013;8:e66454. doi: 10.1371/journal.pone.0066454. - DOI - PMC - PubMed
    1. Herman WH, Ye W, Griffin SJ, et al. Early detection and treatment of type 2 diabetes reduce cardiovascular morbidity and mortality: a simulation of the results of the Anglo-Danish-Dutch study of intensive treatment in people with screen-detected diabetes in primary care (ADDITION-Europe) Diabetes Care. 2015;38:1449–1455. doi: 10.2337/dc14-2459. - DOI - PMC - PubMed

Publication types